Literature DB >> 12853792

Comparison of aminolevulinic acid and hexylester aminolevulinate induced protoporphyrin IX distribution in human bladder cancer.

A Marti1, P Jichlinski, N Lange, J-P Ballini, L Guillou, H J Leisinger, P Kucera.   

Abstract

PURPOSE: Successful photodynamic therapy of epithelial cancer requires a specific photosensitization of malignant tissue. We evaluate the intensity and localization of protoporphyrin IX (PpIX) in superficial transitional cell carcinoma and nonmalignant cells of the human bladder following topical administration of its precursor, either aminolevulinic acid (ALA) or hexylester aminolevulinate (HAL).
MATERIALS AND METHODS: Solutions of ALA or HAL were instilled into the bladder of 18 patients presenting with recurrent transitional cell carcinoma. The distribution of PpIX through the bladder wall was studied on frozen biopsies using fluorescence microscopy and correlated with pathological findings.
RESULTS: Topical bladder instillation with 180 mmol (3%) ALA administered for 6 hours or 8 mmol (0.2%) HAL administered for 4 hours gave similar results regarding intensity and tissue distribution of PpIX fluorescence, whereas 8 mmol HAL administered for 2 hours followed by 2 hours of resting time (2+2 hours concept) induced a PpIX fluorescence twice as high. The fluorescence remained limited to cancer cells. Only a trace of PpIX fluorescence was observed in suburothelial connective tissue, that is chorion, but none in the bladder smooth muscle regardless of experiment conditions.
CONCLUSIONS: HAL is an excellent precursor for PpIX synthesis in bladder cancer. With the 2+2 hour topical administration condition it yielded the highest PpIX fluorescence intensity and fluorescence contrast between normal and malignant urothelial cells. This approach allows us to optimize PpIX tissue distribution for photodynamic therapy in superficial bladder cancer.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12853792     DOI: 10.1097/01.ju.0000075054.38441.2d

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  14 in total

Review 1.  Early bladder cancer: concept, diagnosis, and management.

Authors:  Hiroshi Kitamura; Taiji Tsukamoto
Journal:  Int J Clin Oncol       Date:  2006-02       Impact factor: 3.402

Review 2.  Treatment options for BCG failures.

Authors:  Michael A O'Donnell; Andreas Boehle
Journal:  World J Urol       Date:  2006-11       Impact factor: 4.226

Review 3.  Recent advances in the field of urology.

Authors:  Chester J Koh; Anthony Atala
Journal:  Curr Urol Rep       Date:  2006-01       Impact factor: 3.092

Review 4.  Fluorescence Imaging for Cancer Screening and Surveillance.

Authors:  K E Tipirneni; E L Rosenthal; L S Moore; A D Haskins; N Udayakumar; A H Jani; W R Carroll; A B Morlandt; M Bogyo; J Rao; Jason M Warram
Journal:  Mol Imaging Biol       Date:  2017-10       Impact factor: 3.488

Review 5.  The Impact of Blue Light Cystoscopy on the Diagnosis and Treatment of Bladder Cancer.

Authors:  Eugene J Pietzak
Journal:  Curr Urol Rep       Date:  2017-05       Impact factor: 3.092

Review 6.  Hexaminolevulinate hydrochloride in the detection of nonmuscle invasive cancer of the bladder.

Authors:  Savino M Di Stasi; Francesco De Carlo; Vincenzo Pagliarulo; Francesco Masedu; Cristian Verri; Francesco Celestino; Claus Riedl
Journal:  Ther Adv Urol       Date:  2015-12

Review 7.  Blue-light cystoscopy in the evaluation of non-muscle-invasive bladder cancer.

Authors:  Puck Oude Elferink; J Alfred Witjes
Journal:  Ther Adv Urol       Date:  2014-02

Review 8.  Hexyl aminolevulinate: in the detection of bladder cancer.

Authors:  James E Frampton; Greg L Plosker
Journal:  Drugs       Date:  2006       Impact factor: 9.546

9.  [Photodynamic diagnostics in the urinary tract. Consensus paper of the Working Group for Oncology of the German Society for Urology].

Authors:  A Stenzl; D Jocham; P Jichlinski; K Junker; F König; H van den Bergh; B Volkmer; D Zaak; J E Gschwend
Journal:  Urologe A       Date:  2008-08       Impact factor: 0.639

Review 10.  [Fluorescence cystoscopy at bladder cancer: present trials].

Authors:  D Zaak; A Karl; H Stepp; S Tritschler; D Tilki; M Burger; R Knuechel; C Stief
Journal:  Urologe A       Date:  2007-11       Impact factor: 0.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.